We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

77 hedge funds and large institutions have $512M invested in Pliant Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 18

0.98% less ownership

Funds ownership: 85.51% → 84.53% (-0.98%)

5% less funds holding

Funds holding: 81 → 77 (-4)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

43% less capital invested

Capital invested by funds: $893M → $512M (-$381M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $812K

Holders
77
Holders Change
-4
Holders Change %
-4.94%
% of All Funds
1.35%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
7
Increased
30
Reduced
18
Closed
11
Calls
–
Puts
$812K
Net Calls
-$812K
Net Calls Change
-$623K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.12M
2
Citadel Advisors
Citadel Advisors
Florida
+$2.76M
3
Morgan Stanley
Morgan Stanley
New York
+$2.49M
4
CA
CHI Advisors
New York
+$2.48M
5
WP
Woodline Partners
California
+$2.3M

Top Sellers

1
FCM
Farallon Capital Management
California
-$14.3M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.13M
3
EAM
Eventide Asset Management
Massachusetts
-$6.13M
4
RG
Redmile Group
California
-$1.55M
5
SFM
Sphera Funds Management
Israel
-$1.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$1.26M +$322K +15,180 +26%
PCM
27
Pentwater Capital Management
Florida
$1.01M +$637K +30,000 +100%
GC
28
Grace Capital
Massachusetts
$808K -$207K -9,750 -17%
Millennium Management
29
Millennium Management
New York
$564K +$341K +16,077 +93%
Goldman Sachs
30
Goldman Sachs
New York
$558K +$163K +7,660 +30%
Renaissance Technologies
31
Renaissance Technologies
New York
$506K +$637K +30,000 New
Russell Investments Group
32
Russell Investments Group
United Kingdom
$491K – – –
Swiss National Bank
33
Swiss National Bank
Switzerland
$463K – – –
GCP
34
GSA Capital Partners
United Kingdom
$437K +$549K +25,867 New
AllianceBernstein
35
AllianceBernstein
Tennessee
$410K – – –
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$391K -$212K -10,003 -30%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$384K +$21.1K +995 +5%
Bank of America
38
Bank of America
North Carolina
$327K +$229K +10,784 +125%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$289K +$216K +10,189 +146%
JP Morgan Chase
40
JP Morgan Chase
New York
$280K +$73.2K +3,448 +26%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$276K -$113K -5,338 -25%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$248K – – –
Deutsche Bank
43
Deutsche Bank
Germany
$245K -$9.44K -445 -3%
AIG
44
American International Group
New York
$222K -$6.64K -313 -2%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$218K -$14.7K -692 -5%
SFI
46
Susquehanna Fundamental Investments
Pennsylvania
$201K +$253K +11,936 New
DekaBank Deutsche Girozentrale
47
DekaBank Deutsche Girozentrale
Germany
$195K – – –
Invesco
48
Invesco
Georgia
$189K +$36K +1,698 +18%
SG Americas Securities
49
SG Americas Securities
New York
$189K +$238K +11,225 New
ProShare Advisors
50
ProShare Advisors
Maryland
$182K -$41K -1,933 -15%
1
2
3 4

PLRX Hedge Fund Activity: Q3 2021 in Review

77 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2021, worth a combined $512M — down 43% from $893M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PLRX and 7 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 30 added.

The largest buyer was Vanguard Group, adding an estimated $3.12M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $14.3M sold.

  • 77 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2021, down from 81 in Q2 2021.
  • Funds reported $512M of Pliant Therapeutics stock for Q3 2021, down 43% quarter-over-quarter.
  • 7 funds opened new Pliant Therapeutics positions in Q3 2021 and 11 closed out, a net change of -4 holders.
  • The largest Pliant Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $3.12M added.
  • The largest Pliant Therapeutics seller in Q3 2021 was Farallon Capital Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q3 2021.